0747 GMT - Smith & Nephew's results are slightly better than feared, with the medical technology company's reduced guidance expected, J.P. Morgan analysts write. The company's confirmation that it is exploring strategic options for its orthopedics business is also likely to be welcomed, JPM notes. The company doesn't mention its midterm guidance, and JPM thinks it could be addressed at the full-year results. This will act as an overhang on shares, the analysts say.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments